Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Official Title A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma

NCT05694871 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05694871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05694871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Official Title A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 7, 2023
Completion date
May 31, 2027
Enrollment
77 (actual)
Sites
194

Conditions

As the registry lists them; a condition with its own page is linked.

advanced dedifferentiated liposarcoma, locally advanced dedifferentiated liposarcoma, metastatic dedifferentiated liposarcoma, stage iii soft tissue sarcoma of the trunk and extremities ajcc v8, stage iv soft tissue sarcoma of the trunk and extremities ajcc v8, unresectable dedifferentiated liposarcoma